Literature DB >> 2954263

Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy.

P Weiss, G A Soff, H Halkin, U Seligsohn.   

Abstract

Oral anticoagulants achieve an antithrombotic effect only several days after initiation of treatment. A rapid decline of the vitamin-K dependent natural anticoagulants (proteins C and S) during this period might result in a prothrombic phase. We addressed this question by measuring the rates of decline of these proteins, as well as the vitamin K dependent procoagulants, in two groups of patients: A "high dose group" (n = 7), who received a single 40 mg dose of warfarin, and a "low dose group" (n = 20), who received daily individually adjusted doses. In the high dose group an early and marked decline of factor VII:C and protein C antigen was observed, while levels of the other vitamin K dependent factors were still relatively high. In the low dose group, all these proteins declined more gradually. Mean +/- SD of protein C antigen level at 46 hr was 56 +/- 12% in the low dose group, and only 44 +/- 6% (p less than 0.05) in the high dose group. We conclude that during the initiation of warfarin therapy there is a transient prothrombotic phase, which is less marked in patients given daily adjusted doses.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2954263     DOI: 10.1016/0049-3848(87)90088-0

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  16 in total

1.  Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.

Authors:  B Vadher; D L Patterson; M Leaning
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research.

Authors:  P A Brogan; A Bose; D Burgner; D Shingadia; R Tulloh; C Michie; N Klein; R Booy; M Levin; M J Dillon
Journal:  Arch Dis Child       Date:  2002-04       Impact factor: 3.791

Review 3.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 4.  The interaction between complement component C4b-binding protein and the vitamin K-dependent protein S forms a link between blood coagulation and the complement system.

Authors:  M Hessing
Journal:  Biochem J       Date:  1991-08-01       Impact factor: 3.857

5.  A randomized trial of restarting warfarin at maintenance versus loading doses following an elective procedure.

Authors:  Tammy J Bungard; Jay Mutch; Bruce Ritchie
Journal:  J Thromb Thrombolysis       Date:  2017-11       Impact factor: 2.300

Review 6.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

7.  Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy.

Authors:  Yosuke Ichimura; Harumi Takahashi; Michael T M Lee; Mari Shiomi; Kiyoshi Mihara; Takashi Morita; Yuan-Tsong Chen; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

8.  Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: prospective validation of a prescription model.

Authors:  Johanna H H Van Geest-Daalderop; Barbara A Hutten; Nathalie C V Péquériaux; Marcel Levi; Augueste Sturk
Journal:  J Thromb Thrombolysis       Date:  2008-02-13       Impact factor: 2.300

9.  Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.

Authors:  A Zivelin; L V Rao; S I Rapaport
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

10.  Discontinuation of warfarin is unnecessary in total knee arthroplasty.

Authors:  David A Rhodes; Erik P Severson; Jeffrey T Hodrick; Harold K Dunn; Aaron A Hofmann
Journal:  Clin Orthop Relat Res       Date:  2010-01       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.